CLOs on the Move

Vicor Technology

www.vicortech.com

 
Frp, Web: Vicor Technologies, Inc (OTCBB: VCRT) is a bio-technology company focused on the development and commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients: •at risk of sudden cardiac death or autonomic nervous system dysfunction, and •trauma victims in need of immediate lifesaving intervention.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.vicortech.com
  • 2300 NW Corporate Blvd Ste 123
    Boca Raton, FL USA 33431
  • Phone: 800.998.9964

Executives

Name Title Contact Details

Similar Companies

Accurate Chemical and Scientific Company

Accurate Chemical and Scientific Company is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medstar Surgical

Medstar Surgical is a College Point, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MedSphere Corp

MedSphere Corp is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aniz Inc Support Svc Agency

Aniz Inc Support Svc Agency is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.